Results 21 to 30 of about 2,524 (195)

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab in the FAERS Database. [PDF]

Kans J Med
Introduction. Respiratory syncytial virus (RSV) remains a leading cause of hospitalization among infants. Palivizumab has long been used for RSV prophylaxis in high-risk infants, whereas nirsevimab is a newer long-acting monoclonal antibody approved for ...
Touffaha I, Ablah E, Okut H, Homan G.
europepmc   +2 more sources

Impact of Seasonal Nirsevimab Administration in Infants Born During the RSV Circulation Period on RSV-Related Hospitalizations: A Population-Based Study from Emilia-Romagna, Northern Italy

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in early infancy, with the greatest burden occurring in the first months of life. Following the COVID-19 pandemic, many countries experienced intensified RSV circulation.
Susanna Esposito, Matteo Puntoni, Giuseppe Maglietta, Alessandro De Fanti, Chiara Ghizzi, Giacomo Biasucci, Federico Marchetti, Melodie Olivia Aricò, Gianluca Vergine, Marcello Stella, Battista Guidi, Agnese Suppiej, Francesca Alberghi, Emanuele Filice, Maria Elena Capra, Enrico Valletta, Andrea Miceli, Cristina Malaventura, Beatrice Rita Campana, Valentina Fainardi, Caterina Caminiti   +20 more
doaj   +2 more sources

Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023–2024 Season in Andalusia, Spain (NIRSEGRAND) [PDF]

Vaccines
Background: Nirsevimab was indicated in a population level for all infants < 6 months during the 2023–2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for
David Moreno-Pérez, Aleksandra Korobova, Francisco de Borja Croche-Santander, Ana Cordón-Martínez, Olga Díaz-Morales, Leticia Martínez-Campos, Elena Pérez-González, María del Carmen Martínez-Padilla, Juan Luis Santos-Pérez, Jaime Brioso-Galiana, María Isabel Sánchez-Códez, Jorge Del Diego-Salas, Mario Rivera-Izquierdo, Nicola Lorusso   +13 more
doaj   +2 more sources

Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy

Vaccines
Background: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants, particularly those with risk factors such as prematurity or chronic diseases.
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie Aricò, Angela Lanzoni, Beatrice Rita Campana, Marta Niceforo, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +2 more sources

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria [PDF]

Frontiers in Public Health
BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D’Costa, Verena Kaiser, Klaus Kapelari, Gisa Gerold, Thomas Müller, Ursula Kiechl-Kohlendorfer, Elke Griesmaier   +14 more
doaj   +2 more sources

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants [PDF]

Frontiers in Pediatrics
ObjectiveThis study aims to evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants, highlighting its potential to improve neonatal respiratory health.MethodsWe conducted a retrospective ...
Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun   +5 more
doaj   +2 more sources

Talking to parents about Nirsevimab [poster]

Nirsevimab is an immunisation to protect from Respiratory syncytial virus (RSV). It is available for all infants born between September 2024 and February 2025.
Health Protection Surveillance Centre (HPSC)
openaire   +2 more sources

Evaluation of nirsevimab against rsv infection in infants

, 2023
19 p.ill.,LIST OF TABLES 1 -- BACKGROUND 3 -- 1 BACKGROUND 4 -- 2 METHODS 4 -- 3 CLINICAL EVIDENCE 7 -- 3.1 NIRSEVIMAB IN PRETERM INFANTS 7 -- 3.2 NIRSEVIMAB IN LATE-PRETERM AND TERM INFANTS 9 -- 3.3 MEDLEY TRIAL 14 -- 3.4 HARMONIE TRIAL (PRELIMINARY ...
Desimpel, Fabian
core   +1 more source

First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants [PDF]

Respiratory syncytial virus (RSV) predominantly affects young children, with a peak incidence in temperate regions of the northern hemisphere from October to May.
Scarpaleggia M., Rizzo C, Baldo V., Chironna M., Pariani E, Baldo V, Orsi A, Scarpaleggia M, Icardi G, Orsi A., Panatto D, Pariani E., Giuffrida S., Panatto D., Icardi G., Barbone F, Rizzo C., Giuffrida S, Barbone F., Montomoli E., Chironna M, Montomoli E   +20 more
core   +3 more sources

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in FranceResearch in context

EClinicalMedicine
Summary: Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial virus infections) during the first season of implementation.
Charlotte Ocana de Sentuary, Clara Testard, Marion Lagrée, Maxime Leroy, Lisa Gasnier, Alicia Enes-Dias, Constance Leruste, Diariatou Diallo, Michael Génin, Thameur Rakza, François Dubos   +10 more
doaj   +1 more source